Mertenil

Rosuvastatin, the active ingredient in Mertenil, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use and administration. It lowers elevated cholesterol levels and is prescribed for patients with hypercholesterolemia or at risk of cardiovascular events.

GNH USA supplies Mertenil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk orders across multiple regions.

Rosuvastatin is indicated for lipid disorders and cardiovascular risk management.

Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Primary prevention of cardiovascular events in patients at risk: lowers incidence of myocardial infarction and stroke. Secondary prevention of cardiovascular events: decreases recurrence of cardiovascular events in patients with established disease.

Rosuvastatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Muscle pain (myalgia) - Abdominal discomfort - Nausea - Constipation - Dizziness

Serious or Rare Side Effects: - Rhabdomyolysis with muscle breakdown - Severe liver enzyme elevation - Acute renal failure - Anaphylactic reactions - Myopathy with marked CK rise

When prescribing rosuvastatin, clinicians should observe several precautionary measures to ensure patient safety.

Monitor liver function: baseline and periodic liver enzyme tests are recommended. Assess renal function: dose adjustment may be needed in severe renal impairment. Evaluate for muscle symptoms: discontinue if unexplained muscle pain or weakness occurs. Avoid use in pregnancy: contraindicated due to fetal risk. Review concomitant medications: assess for potential drug interactions. Store at room temperature: keep in original pack, protect from moisture.

Rosuvastatin interacts with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Cyclosporine: markedly increases rosuvastatin plasma concentrations. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): elevate rosuvastatin levels. - High‑dose niacin: enhances risk of muscle toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, monitor INR. - Digoxin: possible increase in serum digoxin concentrations. - Antidiabetic agents: rosuvastatin may affect glucose control, monitor blood sugar. - Other statins: combined therapy can increase muscle toxicity risk.